Exhaustive Toxicological Study Guide: Insecticides, Repellents, and Rodenticides

Insecticides and Repellents

  • Mothball Toxicity and Identification:

    • Chemical Composition by Region:

      • United States: Active ingredients are predominantly naphthalene or paradichlorobenzene (also referred to as parabaptorobenzene, pyridine chlorobenzene, or paraglutrolinazine).

      • International: Formulations in other countries frequently utilize camphor.

    • Physical Differentiation via Flotation Tests:

      • Water Test: Camphor mothballs float in water; naphthalene and paradichlorobenzene mothballs sink to the bottom.

      • Saturated Salt or Sugar Solution Test: Naphthalene mothballs float in a saturated salt or sugar solution, whereas paradichlorobenzene mothballs sink to the bottom in water.

    • Naphthalene Characteristics and Mechanism:

      • Chemical Properties: Naphthalene is a terpene derivative or crude oil-like derivative. It serves as the primary active ingredient in older mothball formulations.

      • Formulations: Solid blocks, cakes, and loose forms designed to emit volatile vapors that kill adult moths and intermediate larval stages.

      • Vapor Release: Emits vapors through intact product packaging. Pets (dogs and cats) can suffer respiratory or ocular exposure while the product is still enclosed in its original container. Irritation worsens significantly once opened in an enclosed space.

    • Comparative Toxicity:

      • Naphthalene: Significantly more toxic than paradichlorobenzene. Induces vomiting, methemoglobinemia, metabolic acidosis, anemia, hepatotoxicity, and nephrotoxicity at high doses.

      • Paradichlorobenzene: Safer relative to naphthalene; primarily induces gastrointestinal (GI) irritation ranging from mild to severe based on dose and exposure duration.

    • Decontamination Protocol:

      • Emesis: Induce emesis within the first 44\,hours of ingestion.

      • Adsorbents & Cathartics: Administer activated charcoal with a cathartic if exposure exceeds 44\,hours or if emesis failed to evacuate all ingested material.

      • Methemoglobinemia Management: Administer Methylene Blue as an antidote, particularly for naphthalene ingestion.

      • Supportive Care: Fluid therapy and symptomatic management.

  • Diethyltoluamide (DEET) Toxicity:

    • Overview & Indications: An active ingredient in sprays, repellents, and wearables (e.g., Off! Deep Woods products) designed to repel mosquitoes and arthropods.

    • Labeling Regulations: EPA mandates explicit product labeling ( "contains DEET" or "DEET-free" ) due to toxic reactions in sensitive populations, particularly immature females, cats, and human children.

    • Clinical Presentation:

      • Systemic & Neurological: Vomiting, excitation, tremors, and acute neurological dysfunction.

      • Dermal: Localized erythema, skin irritation, and scarring at application or wearable sites.

  • Boric Acid Toxicity:

    • Usage: Applied as a powder around door thresholds, windows, and plumbing fixtures for cockroach control.

    • Toxic Profile: Possesses low overall mammalian toxicity; however, ingestion induces gastrointestinal distress and mucosal lesions depending on dose and exposure duration.

    • Clinical Screening: History taking must evaluate pet access to perimeter application sites.

  • Citrus Oil Extracts:

    • Overview: Natural extract insecticides considered safe for canine use, but highly toxic to feline patients.

    • Mechanism of Exposure: Feline toxicosis commonly occurs when canine-recommended label dosages are inadvertently applied to cats.

  • Insecticide Synergists: Piperonyl Butoxide (PBO):

    • Mechanism: Inhibits insect detoxification enzymes (mixed-function oxidases), extending the half-life and efficacy of short-acting insecticides such as pyrethroids.

    • Safety Concerns: Evaluated for potential toxicity enhancement in host mammalian species when co-formulated with insecticides.

Rodenticides: General Principles and Risk Factors

  • Hazard Profile and Regulation:

    • Rodenticides represent the most acutely toxic pesticide class in veterinary medicine.

    • Strictly regulated by the EPA; high-potency products are restricted to registered pesticide applicators.

    • Mandated Safety Features: EPA requires manufacturers to include bright, intense dye colors (e.g., vivid fluorescent green) to aid in ingestion identification, as well as emetics to induce protective vomiting in non-target species.

  • Exposure Vectors:

    • Application Placement: Placed along pest runways, hiding spots, entry/exit points, and plumbing lines.

    • Accidental Ingestion Sources: Inappropriate storage, overuse, environmental spills, and accessible trash containers.

  • Toxicological Concepts:

    • Target vs. Non-Target Species: Target species are the intended target pests (e.g., rodents). Because rodents share mammalian cellular and biochemical mechanisms with dogs, cats, and humans, creating rodenticides non-toxic to pets is difficult compared to herbicides or fungicides.

    • Relay Toxicosis (Secondary Toxicosis): Poisoning that occurs when a non-target predator or scavenger consumes the carcass of an animal killed by rodenticide.

    • Environmental Persistence: Dependent on environmental half-life, usage conditions, and carcass/trash management.

Anticoagulant Rodenticides

  • Historical Development:

    • Sweet Clover Disease: Identified in the United States and Canada following fatal hemorrhagic outbreaks in cattle fed moldy sweet clover.

    • Chemical Conversion: Unmolded sweet clover contains non-toxic coumarin. Fungal/mold contamination dimerizes coumarin into dicumarol (dicoumarin).

    • Discovery of Warfarin: Research at the University of Wisconsin, funded by the Wisconsin Alumni Research Foundation (WARF), isolated dicumarol and synthesized warfarin.

    • Therapeutic Applications: Synthetic derivatives (Coumadin) are used for human and equine thrombotic disorders, such as aortic saddle thrombi in cats (aortic bifurcation thrombosis causing hindlimb paralysis and loss of pain sensation).

  • Classification and Generations:

    • First-Generation Anticoagulants:

      • Prototype: Warfarin (plasma half-life approx. 1414\,hours).

      • Characteristics: Lower potency, shorter duration of action; requires multiple consecutive feedings by rodents to produce lethality.

      • Treatment Duration: Typically requires 3–73\text{--}7\,days of medical management in pets.

    • Second-Generation Anticoagulants:

      • Examples: Brodifacoum, Bromadiolone.

      • Characteristics: High potency, long tissue half-life; lethal after a single feed.

      • Treatment Duration: Requires prolonged antidote therapy (under 2020\,days to 3030\,days).

    • Chemical Structural Classes: Coumarins and Indandiones.

    • Bait Formulations: Concentrations range between 0.02%0.02\%\,and\,1.0%1.0\%\,in blocks, pellets, or pastes. EPA registration numbers on packaging provide exact chemical concentration details.

  • Toxicokinetics and Pharmacodynamics:

    • Absorption & Distribution: Rapidly absorbed from the GI tract with high plasma protein (albumin) binding.

    • Metabolism & Elimination: Hepatic metabolism via mixed-function oxidases (MFOs) into hydroxylated metabolites; excreted by kidneys with variable enterohepatic recirculation.

    • Mechanism of Action:

      • Competitively inhibits Vitamin K1 epoxide reductase.

      • Prevents gamma-carboxylation and activation of clotting factors: Factor II (prothrombin), Factor VII, Factor IX, and Factor X.

    • Latent Period: Clinical signs do not appear immediately. Hemorrhage is delayed 24–4824\text{--}48\,hours post-ingestion until existing circulating functional clotting factors are depleted. Factor VII has the shortest half-life and is depleted first.

    • Drug Interactions: Highly protein-bound drugs (e.g., sulfonamides, phenylbutazone, phenobarbital) compete for albumin binding sites, displacing the anticoagulant, elevating free toxin levels, and potentiating toxicosis.

  • Clinical Presentation:

    • Signs: Generalized or localized hemorrhage, lethargy, pale mucous membranes, weakness, epistaxis, hematemesis, melena, hematuria, hemothorax, hypovolemic shock, and sudden death.

    • Atypical Presentations: Severe internal bleeding without external signs (e.g., isolated fatal intracranial hemorrhage, hemarthrosis, or subcutaneous hematomas over pressure points and joints).

    • Large Animal Presentation: Post-surgical/castration hemorrhage in cattle herds sharing moldy forage.

  • Diagnostics:

    • Prothrombin Time (PT): Extrinsic pathway test; prolongs first (typically 22\,to\,66\,times normal baseline) due to rapid Factor VII depletion.

    • Activated Partial Thromboplastin Time (aPTT) & Activated Coagulation Time (ACT): Prolonged later in toxicosis.

    • Platelet Count: Typically remains within normal limits (distinguishing anticoagulant toxicity from primary immune-mediated thrombocytopenia).

    • Confirmatory Diagnostics: Analytical chemistry of liver tissue, stomach contents, or blood.

  • Therapeutic Protocol:

    • Decontamination: Administer activated charcoal to limit absorption and interrupt enterohepatic recycling.

    • Antidotal Therapy: Vitamin K1 (Phytonadione).

      • Route: Subcutaneous (SC), Intramuscular (IM), or Per Os (PO). NEVER Intravenous (IV) due to severe anaphylactoid risks.

      • Administration Note: Administer oral Vitamin K1 alongside a fatty meal to maximize intestinal absorption.

    • Transfusion Therapy: Fresh whole blood or fresh frozen plasma (FFP) provides immediate replenishment of active clotting factors.

    • Supportive Care: Cage rest, warmth, hydration monitoring, serial PCV/TP tracking, and oxygen therapy.

Cholecalciferol (Vitamin D3) Rodenticides

  • Properties and Background:

    • Properties: Lipid-soluble vitamin (Vitamin A,D,E,K\text{Vitamin } A, D, E, K) with high tissue storage, membrane permeability, and long biological half-life (unlike water-soluble Vitamins B and C\text{Vitamins } B \text{ and } C which are flushed in urine).

    • Formulation: Baited at 0.075%0.075\%\,concentration; induces lethal toxicosis in rodents after a single feeding within 1–31\text{--}3\,days.

    • Alternative Exposure Sources: Over-supplemented pet foods, livestock feed additives, human Vitamin D3 supplements, and improper breeder over-supplementation.

  • Pathophysiology:

    • Disrupts calcium (Ca2+Ca^{2+}) and phosphorus (PP) homeostasis.

    • Induces osteoclastic bone resorption, GI calcium absorption, and renal calcium reabsorption.

    • Results in severe hypercalcemia and hyperphosphatemia.

    • Metastatic Soft Tissue Mineralization: Calcium-phosphate deposits form white crystalline residues on serosal surfaces of major organs, renal tubules, cardiac tissue, small arterioles, and intestinal mucosa.

    • Organ Dysfunction:

      • Renal Failure: Mineralization of renal tubules leads to polyuria/polydipsia (PU/PD), tubular necrosis, elevated Blood Urea Nitrogen (BUN), elevated Creatinine, and reduced urine specific gravity.

      • Cardiovascular System: Hypercalcemia increases myocardial contractility force and speed, inducing arrhythmias and myocardial serosal calcification.

  • Diagnostics:

    • Serum Biochemistry: Severe hypercalcemia, hyperphosphatemia, elevated BUN, elevated creatinine, and elevated active 1,25-hydroxyvitamin D1,25\text{-hydroxyvitamin D}\,(1,25-(OH)2D31,25\text{-(OH)}_2\text{D}_3).

    • Urinalysis: Low urine specific gravity (isosthenuria).

    • Pathology: Raised arterial intimal plaques, calcified myocardial serosa, and widespread organ mineralization.

  • Treatment Protocol:

    • Decontamination: Induce emesis (if acute and non-seizuring), followed by activated charcoal and a saline cathartic.

      • Absolute Contraindications for Emesis: Active seizures, corrosive/alkaline ingestion, hydrocarbon/petroleum ingestion, pre-existing esophageal stricture, or non-vomiting species.

    • Hypercalcemia Management:

      • Fluid Therapy: 0.9%0.9\%\,NaCl IV fluids to promote renal calciuresis.

      • Glucocorticoids: Enhance renal calcium excretion and reduce GI absorption.

      • Pamidronate: Bisphosphonate compound that directly inhibits osteoclastic bone resorption (preferred over Salmon Calcitonin due to lower cost and absence of refractory downregulation).

      • Note: Do not co-administer Pamidronate and Salmon Calcitonin.

Non-Target Animal Toxicoses and Calcinogenic Plants

  • Enzootic Hypercalcemia:

    • Occurs in livestock in South America (e.g., Brazil) consuming calcinogenic plants.

    • Plants contain Vitamin D-like glycosides that induce hypercalcemia, hyperphosphatemia, and severe soft tissue mineralization identical to cholecalciferol toxicosis.

Clinical Case Studies and Audience Interactions

  • Case Study: Anticoagulant Rodenticide Ingestion (Fred the Dog):

    • History: Consumed 66\,ounces of rodenticide bait 55\,days prior in a barn setting.

    • Progression: Initial emesis post-ingestion followed by a 2–32\text{--}3\,day subclinical latent period. Anorexia and left knee bruising developed on Day 4.

    • Presentation (Day 5): Weakness, ataxia, unwillingness to move, active epistaxis, pulmonary hemorrhage, rectal bleeding, hematemesis, melena, hematuria, and subcutaneous hematomas over pressure points.

  • Audience Interactions & Discussions:

    • Fat-Soluble vs. Water-Soluble Vitamins: Vitamins A, D, E, K are fat-soluble (high accumulation and toxicity potential); Vitamins B and C are water-soluble (readily excreted).

    • Contraindications for Emesis: Seizuring patients, corrosive ingestions, petroleum distillates, and non-vomiting species.